Precision oncology platform that profiles tumor DNA and RNA to rank 170+ targeted and immunotherapy drugs for each patient.
Oncobox Dx analyzes tumor genomics to predict the effectiveness of over 170 targeted and immunotherapy drugs, generating a personalized drug ranking with molecular abnormality reports and clinical trial outcomes for oncologists. The system has been validated in retrospective and prospective trials with hundreds of late-stage cancer patients. Testing is accessed through affiliated clinics that send tumor samples to the Oncobox laboratory for comprehensive genomic profiling. Oncobox holds a USPTO patent for its genetic information analysis platform. Oncobox Dx is a product of Oncobox.